Pehub.com -- Promethera Biosciences, a Belgium-based stem cell therapy company, has raised €5.3 million in new Series A funding. Vesalius Biocapital led the round, and was joined by SRIW, Life Sciences Research Partners, NivelInvest, Capital & Croissance, LRM Oxygen for Growth, Vives and return backer Sopartec.